Site-selective modification strategies in antibody–drug conjugates-Reference-Cited by-同舟云学术

Site-selective modification strategies in antibody–drug conjugates

Published:2021 Issue:2 Volume:50 Page:1305-1353
ISSN:0306-0012
Container-title:Chemical Society Reviews
language:en
Short-container-title:Chem. Soc. Rev.

Author:

Walsh Stephen J.¹²³⁴⁵^ORCID,Bargh Jonathan D.¹²³⁴⁵^ORCID,Dannheim Friederike M.¹²³⁴⁵^ORCID,Hanby Abigail R.¹²³⁴⁵,Seki Hikaru¹²³⁴⁵^ORCID,Counsell Andrew J.¹²³⁴⁵^ORCID,Ou Xiaoxu¹²³⁴⁵^ORCID,Fowler Elaine¹²³⁴⁵^ORCID,Ashman Nicola¹²³⁴⁵^ORCID,Takada Yuri¹²³⁴⁵^ORCID,Isidro-Llobet Albert⁶⁷⁸⁵^ORCID,Parker Jeremy S.⁹¹⁰¹¹¹²⁵^ORCID,Carroll Jason S.¹³¹⁴⁴⁵^ORCID,Spring David R.¹²³⁴⁵^ORCID

Affiliation:

1. Department of Chemistry

2. University of Cambridge

3. Lensfield Road

4. Cambridge

5. UK

6. GSK

7. Gunnels Wood Road

8. Stevenage

9. Early Chemical Development

10. Pharmaceutical Development

11. R&D, AstraZeneca

12. Macclesfield

13. Cancer Research UK Cambridge Institute

14. University of Cambridge, Robinson Way

Abstract

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an antibody to deliver a cytotoxic payload to specific cell types. This review summarises the advances made in the construction of homogenous ADCs.

Funder

Engineering and Physical Sciences Research Council

Biotechnology and Biological Sciences Research Council

AstraZeneca

Cambridge Trust

Trinity College, University of Cambridge

Uehara Memorial Foundation

Japan Society for the Promotion of Science

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemistry